Diego Teyssonneau
Diego Teyssonneau is an expert in Oncology at Institut Bergonié (France). Diego Teyssonneau has authored 22 publications, the most recent in 2025, and is an investigator in 13 clinical trials, 9 of them ongoing. SLR score: 295 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Urology - Radiotherapy - Hematology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2017 - 2025
Number : 22
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Impact of FGFR3 Alterations on First-Line Platinum Based Chemotherapy in Patients With Metastatic or Locally Advanced Urothelial Carcinoma: The Retrospective IFUCA Study. PMID 41349225 — urinary bladder neoplasms, neoplasms, drug therapy, prostatic neoplasms, kidney neoplasms, therapeutics, chemotherapy | Clin Genitourin Cancer | 2025 | 0 |
| Toxicities of novel androgen receptor pathway inhibitor targeted therapies in advanced prostate cancer. PMID 40970404 — pharmaceutical preparations, androgens, receptors, androgen, neoplasms, prostate, drug-related side effects and adverse reactions, physicians, prostatic neoplasms, therapeutics | Curr Opin Urol | 2025 | 0 |
| Short-term Darolutamide (ODM-201) Concomitant to Radiation Therapy for Patients with Unfavorable Intermediate-risk Prostate Cancer: The Darius (AFU-GETUG P15) Phase 2 Trial Protocol. PMID 38755095 — radiotherapy, clinical protocols, disease-free survival, pharmaceutical preparations, androgens, neoplasms, prostate, urologic neoplasms, prostatic neoplasms, therapeutics | Eur Urol Oncol | 2024 | 2 |
| Tertiary lymphoid structures and cancer immunotherapy: From bench to bedside. PMID 39798544 — neoplasms, tertiary lymphoid structures, immunotherapy, immunity, therapeutics | Med | 2025 | 3 |
| Analysis of PD1, LAG3, TIGIT, and TIM3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy response. PMID 39591972 — cells, genes, lung, lymphocytes, biological science disciplines, neoplasms, adenocarcinoma, carcinoma, non-small-cell lung, adenocarcinoma of lung, biomarkers, immunotherapy, immune checkpoint inhibitors, cell death, tumor microenvironment | Cell Rep Med | 2024 | 5 |
Clinical Studies 13
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
9 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A clinical trial to learn about the effects of AMO959 given with AAA617 and an androgen receptor pathway inhibitor (ARPI) in adults with PSMA positive prostate cancer that has spread to other parts of the body pathway inhibitor (ARPI) in adults with PSMA positive prostate cancer that has spread to other parts of the body 2025-521859-23-00 — protein kinases, androgens, receptors, androgen, neoplasms, multiple chronic conditions, prostate, protein kinase inhibitors, prostatic neoplasms, castration, dna | Phase 1/Phase 2 | Recruiting | 2026 |
| A Study of Vepugratinib (LY3866288) in Participants with Cancer in the Urinary Tract ( FORAGER 2 ) 2025-522855-25-00 — urinary bladder, carcinoma, transitional cell, urinary bladder neoplasms, cells, safety, urinary tract, neoplasms, neoplasm metastasis, carcinoma | Phase 3 | Not yet recruiting | 2026 |
| A Clinical Trial to Assess a New Anti Cancer Treatment (called DSB2455) Given On Its Own in Patients with Advanced Malignancies 2023-508805-26-00 — neoplasms, therapeutics | Phase 1 | Not yet recruiting | 2024 |
| A Phase 1 Study of JNJ 87189401 Combined with JNJ 78278343 for Advanced Prostate Cancer 2023-504063-17-00 — neoplasms, prostate, prostatic neoplasms | Phase 1 | Recruiting | 2024 |
| Dato DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la mUC 2024-516906-47-00 — therapeutics, carboplatin, carcinoma | Phase 2/Phase 3 | Recruiting | 2025 |
LeadR Networks
Main global connection map